Laurus Labs, a company in the Pharmaceuticals industry, reported revenue of ₹2,206 crore and net profit of ₹436 crore for the September 2026 quarter.
Laurus Labs (NSE: LAURUSLABS) closed at ₹2,294.60 on 20 Nov 2026, up 132.5% over the past year. Its market capitalisation is ₹1,23,980 crore and it trades at 92.5 times earnings.
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.